{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:41:41Z","timestamp":1787064101624,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13555-025-01644-3","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:58:48Z","timestamp":1768813128000},"page":"1309-1330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study"],"prefix":"10.1007","volume":"16","author":[{"given":"Jonathan I.","family":"Silverberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Bagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rosmarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Chovatiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Zirwas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Waibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny E.","family":"Murase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Lockshin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Weisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber Reck","family":"Atwater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Proper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Silk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangeline","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lucia Buziqui","family":"Piruzeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Montmayeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinglin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreekumar","family":"Pillai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"1644_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2500\/aap.2019.40.4202","volume":"40","author":"J Kim","year":"2019","unstructured":"Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc. 2019;40:84\u201392.","journal-title":"Allergy Asthma Proc"},{"key":"1644_CR2","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jaad.2023.08.103","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90:342\u20135.","journal-title":"J Am Acad Dermatol"},{"key":"1644_CR3","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s13555-023-00947-7","volume":"13","author":"AJ Okragly","year":"2023","unstructured":"Okragly AJ, Ryuzoji A, Wulur I, et al. Binding, neutralization and internalization of the interleukin-13 antibody, lebrikizumab. Dermatol Ther (Heidelb). 2023;13:1535\u201347.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1644_CR4","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2206714","volume":"388","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Guttman-Yassky E, Tha\u00e7i D, et al. Two phase\u00a03 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388:1080\u201391.","journal-title":"N Engl J Med"},{"key":"1644_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","volume":"156","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase\u00a02b randomized clinical trial. JAMA Dermatol. 2020;156:411\u201320.","journal-title":"JAMA Dermatol"},{"key":"1644_CR6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/jamadermatol.2022.5534","volume":"159","author":"EL Simpson","year":"2023","unstructured":"Simpson EL, Gooderham M, Wollenberg A, et al. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). JAMA Dermatol. 2023;159:182\u201391.","journal-title":"JAMA Dermatol"},{"key":"1644_CR7","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1007\/s13555-023-00942-y","volume":"13","author":"AS Paller","year":"2023","unstructured":"Paller AS, Flohr C, Eichenfield LF, et al. Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: a 52-week, open-label, phase\u00a03 study. Dermatol Ther (Heidelb). 2023;13:1517\u201334.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1644_CR8","doi-asserted-by":"publisher","first-page":"ii3","DOI":"10.1093\/bjd\/ljad498.005","volume":"190","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Weidinger S, Simpson E, et al. Efficacy and safety of lebrikizumab is maintained to two years in patients with moderate-to-severe atopic dermatitis. Br J Dermatol. 2024;190:ii3\u20134.","journal-title":"Br J Dermatol"},{"key":"1644_CR9","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1093\/bjd\/ljad022","volume":"188","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Thyssen JP, Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase\u00a0III trials. Br J Dermatol. 2023;188:740\u20138.","journal-title":"Br J Dermatol"},{"key":"1644_CR10","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","volume":"78","author":"EL Simpson","year":"2018","unstructured":"Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase\u00a0II trial (TREBLE). J Am Acad Dermatol. 2018;78:863-71.e11.","journal-title":"J Am Acad Dermatol"},{"key":"1644_CR11","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s40257-025-00970-8","volume":"26","author":"A Alexis","year":"2025","unstructured":"Alexis A, Moiin A, Waibel J, et al. Efficacy and safety of lebrikizumab in adult and adolescent patients with skin of color and moderate-to-severe atopic dermatitis: results from the phase\u00a0IIIb, open-label ADmirable study. Am J Clin Dermatol. 2025;26:803\u201317.","journal-title":"Am J Clin Dermatol"},{"key":"1644_CR12","unstructured":"FDA approves Lilly\u2019s EBGLYSS\u2122 (lebrikizumab-lbkz) for adults and children 12\u00a0years and older with moderate-to-severe atopic dermatitis. Sep 13, 2024. https:\/\/www.prnewswire.com\/news-releases\/fda-approves-lillys-ebglyss-lebrikizumab-lbkz-for-adults-and-children-12-years-and-older-with-moderate-to-severe-atopic-dermatitis-302248062.html"},{"key":"1644_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/17512433.2018.1449642","volume":"11","author":"M Seegraber","year":"2018","unstructured":"Seegraber M, Srour J, Walter A, Knop M, Wollenberg A. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018;11:467\u201374.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1644_CR14","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","volume":"78","author":"MJ Gooderham","year":"2018","unstructured":"Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78:S28-36.","journal-title":"J Am Acad Dermatol"},{"key":"1644_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cea.13491","volume":"50","author":"H Harb","year":"2020","unstructured":"Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy. 2020;50:5\u201314.","journal-title":"Clin Exp Allergy"},{"key":"1644_CR16","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase\u00a03 trial. Lancet. 2017;389:2287\u2013303.","journal-title":"Lancet"},{"key":"1644_CR17","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s13555-023-00965-5","volume":"13","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Delevry D, Yang M, et al. Long-term effectiveness of dupilumab in patients with atopic dermatitis: results up to 3\u00a0years from the RELIEVE-AD study. Dermatol Ther (Heidelb). 2023;13:2107\u201320.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1644_CR18","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1111\/1346-8138.17017","volume":"51","author":"DH Kang","year":"2024","unstructured":"Kang DH, Kwon SH, Lew BL. Four-year long-term drug survival of dupilumab analyzed by treatment period in patients with moderate to severe atopic dermatitis: a real-world retrospective study. J Dermatol. 2024;51:e63\u20135.","journal-title":"J Dermatol"},{"key":"1644_CR19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/bjd.20883","volume":"186","author":"M-E Marniquet","year":"2022","unstructured":"Marniquet M-E, Seneschal J, Darrigade A-S, et al. Reasons for discontinuation of dupilumab in adult atopic dermatitis in clinical practice. Br J Dermatol. 2022;186:733\u20135.","journal-title":"Br J Dermatol"},{"key":"1644_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","volume":"81","author":"S Faiz","year":"2019","unstructured":"Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81:143\u201351.","journal-title":"J Am Acad Dermatol"},{"key":"1644_CR21","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase\u00a03 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335\u201348.","journal-title":"N Engl J Med"},{"key":"1644_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","volume":"10","author":"JM Hanifin","year":"2001","unstructured":"Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The Eczema Area and Severity Index (EASI): assessment of reliability in atopic dermatitis. EASI evaluator group. Exp Dermatol. 2001;10:11\u20138.","journal-title":"Exp Dermatol"},{"key":"1644_CR23","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jaad.2015.09.062","volume":"74","author":"M Futamura","year":"2016","unstructured":"Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol. 2016;74:288\u201394.","journal-title":"J Am Acad Dermatol"},{"key":"1644_CR24","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134.","journal-title":"JAMA"},{"key":"1644_CR25","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1007\/s12325-024-02802-3","volume":"41","author":"A Rams","year":"2024","unstructured":"Rams A, Baldasaro J, Bunod L, et al. Assessing itch severity: content validity and psychometric properties of a patient-reported pruritus numeric rating scale in atopic dermatitis. Adv Ther. 2024;41:1512\u201325.","journal-title":"Adv Ther"},{"key":"1644_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s41687-024-00764-2","volume":"8","author":"A Rams","year":"2024","unstructured":"Rams A, Baldasaro J, Bunod L, et al. Sleep-loss related to itch in atopic dermatitis: assessing content validity and psychometric properties of a patient-reported sleep-loss rating scale. J Patient Rep Outcomes. 2024;8:77.","journal-title":"J Patient Rep Outcomes"},{"key":"1644_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s12955-021-01877-8","volume":"19","author":"JI Silverberg","year":"2021","unstructured":"Silverberg JI, Delozier A, Sun L, et al. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis. Health Qual Life Outcomes. 2021;19:247.","journal-title":"Health Qual Life Outcomes"},{"key":"1644_CR28","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210\u20136.","journal-title":"Clin Exp Dermatol"},{"key":"1644_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/03007995.2019.1699516","volume":"36","author":"DM Pariser","year":"2020","unstructured":"Pariser DM, Simpson EL, Gadkari A, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis\u00a0Control Tool (ADCT). Curr Med Res Opin. 2020;36:367\u201376.","journal-title":"Curr Med Res Opin"},{"key":"1644_CR30","doi-asserted-by":"crossref","unstructured":"Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on atopic dermatitis. Dermatology. 1993;186:23\u201331.","DOI":"10.1159\/000247298"},{"key":"1644_CR31","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/j.1365-2133.2008.08487.x","volume":"158","author":"T Ruzicka","year":"2008","unstructured":"Ruzicka T, Lynde CW, Jemec GBE, et al. Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008;158:808\u201317.","journal-title":"Br J Dermatol"},{"key":"1644_CR32","unstructured":"Dupixent FDA approval history. 2024. https:\/\/www.drugs.com\/history\/dupixent.html"},{"key":"1644_CR33","doi-asserted-by":"publisher","first-page":"AB148","DOI":"10.1016\/j.jaci.2022.12.463","volume":"151","author":"E Sher","year":"2023","unstructured":"Sher E, Boguniewicz M, Golant A, et al. Efficacy of lebrikizumab in patients with atopic dermatitis and atopic comorbidities: pooled results from two phase\u00a03 monotherapy randomized, double-blind, placebo-controlled 16-week studies (ADvocate1 and ADvocate2). J Allergy Clin Immunol. 2023;151:AB148.","journal-title":"J Allergy Clin Immunol"},{"key":"1644_CR34","doi-asserted-by":"publisher","first-page":"ljad162.010","DOI":"10.1093\/bjd\/ljad162.010","volume":"188","author":"L Stein Gold","year":"2023","unstructured":"Stein Gold L, Gutermuth J, Adam DN, et al. Lebrikizumab provides clinically meaningful improvements in atopic dermatitis in patients previously treated with dupilumab. Br J Dermatol. 2023;188:ljad162.010.","journal-title":"Br J Dermatol"},{"key":"1644_CR35","doi-asserted-by":"publisher","DOI":"10.25251\/skin.8.supp.451","volume":"8","author":"C Bunick","year":"2024","unstructured":"Bunick C, Magnolo N, Moore A, et al. Switching from dupilumab to upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis and inadequate response to dupilumab: efficacy and safety results from the phase\u00a03b\/4 LEVEL UP study. J of Skin. 2024;8:s451.","journal-title":"J of Skin"},{"key":"1644_CR36","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jaad.2022.04.009","volume":"87","author":"VY Shi","year":"2022","unstructured":"Shi VY, Bhutani T, Fonacier L, et al. Phase\u00a03 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND). J Am Acad Dermatol. 2022;87:351\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1644_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19108","author":"G Licata","year":"2023","unstructured":"Licata G, Tancredi V, Pezzolo E, et al. Efficacy and safeness of tralokinumab in patients with atopic dermatitis who developed conjunctivitis under dupilumab: a case series. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.19108.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1644_CR38","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/ced\/llad038","volume":"48","author":"AR Schl\u00f6sser","year":"2023","unstructured":"Schl\u00f6sser AR, Shareef M, Olydam J, Nijsten TEC, Hijnen DJ. Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice. Clin Exp Dermatol. 2023;48:510\u20137.","journal-title":"Clin Exp Dermatol"},{"key":"1644_CR39","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jaip.2024.12.001","volume":"13","author":"A Beyrouti","year":"2025","unstructured":"Beyrouti A, Deuze J, Fontas E, et al. Switching from dupilumab to tralokinumab or janus kinase inhibitors in cases of ocular and\/or facial adverse events in oatients with atopic dermatitis: a multicenter retrospective study. J Allergy Clin Immunol Pract. 2025;13:353\u201360.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1644_CR40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/ijd.16926","volume":"63","author":"M Lasheras-P\u00e9rez","year":"2024","unstructured":"Lasheras-P\u00e9rez M, Palacios-Diaz R, Pozuelo-Ruiz M, Torres-Navarro I, Botella-Estrada R, Rodriguez-Serna M. Switching from dupilumab to tralokinumab in patients with atopic dermatitis due to inefficacy or side effects. Int J Dermatol. 2024;63:105\u20137.","journal-title":"Int J Dermatol"},{"key":"1644_CR41","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jdcr.2024.01.021","volume":"46","author":"E Herman","year":"2024","unstructured":"Herman E, Burgy J, Shahriari M. A retrospective multicenter case series of real-world tralokinumab use in dupilumab-experienced patients. JAAD Case Rep. 2024;46:40\u20134.","journal-title":"JAAD Case Rep"},{"key":"1644_CR42","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/cea.14305","volume":"53","author":"R Achten","year":"2023","unstructured":"Achten R, Dekkers C, Bakker D, et al. Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: preliminary case series. Clin Exp Allergy. 2023;53:586\u20139.","journal-title":"Clin Exp Allergy"},{"key":"1644_CR43","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.jaad.2024.08.019","volume":"91","author":"S George","year":"2024","unstructured":"George S, Yu J. Tralokinumab as an effective alternative after dupilumab treatment failure in moderate-to-severe atopic dermatitis: a real-world study. J Am Acad Dermatol. 2024;91:1228\u201330.","journal-title":"J Am Acad Dermatol"},{"key":"1644_CR44","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2025.0046","author":"T Hagino","year":"2025","unstructured":"Hagino T, Uchiyama A, Onda M, et al. Real-world Japanese study of the effectiveness and safety of switching from dupilumab to lebrikizumab in patients with moderate to severe atopic dermatitis. Dermatitis. 2025. https:\/\/doi.org\/10.1089\/derm.2025.0046.","journal-title":"Dermatitis"},{"key":"1644_CR45","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0140-6736(24)01238-8","volume":"404","author":"Y Renert-Yuval","year":"2024","unstructured":"Renert-Yuval Y, Guttman-Yassky E. Hands-on: a novel JAK inhibitor for the treatment of chronic hand eczema. Lancet. 2024;404:409\u201311.","journal-title":"Lancet"},{"key":"1644_CR46","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jaad.2023.04.052","volume":"89","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Simpson B, Abuabara K, et al. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: a cross sectional study from the TARGET-DERM AD cohort. J Am Acad Dermatol. 2023;89:519\u201328.","journal-title":"J Am Acad Dermatol"},{"key":"1644_CR47","doi-asserted-by":"crossref","unstructured":"Ronnstad ATM, Thomsen SF, Thyssen JP, Egeberg A. The burden of head-and-neck dermatitis in adults with atopic dermatitis and its association with asthma, rhinitis, and disease severity. J Am Acad Dermatol. 2023;90:616\u201318.","DOI":"10.1016\/j.jaad.2023.10.042"},{"key":"1644_CR48","first-page":"22","volume":"16","author":"AM Snyder","year":"2023","unstructured":"Snyder AM, Taliercio VL, Brandenberger AU, et al. Atopic dermatitis: a qualitative study on the burdens of living with itchiness. J Clin Aesthet Dermatol. 2023;16:22\u20135.","journal-title":"J Clin Aesthet Dermatol"},{"key":"1644_CR49","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults. Ann Allergy Asthma Immunol. 2018;121:340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1644_CR50","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40257-023-00804-5","volume":"24","author":"MJ Woodbury","year":"2023","unstructured":"Woodbury MJ, Smith JS, Merola JF. Dupilumab-associated arthritis: a dermatology\u2013rheumatology perspective. Am J Clin Dermatol. 2023;24:859\u201364.","journal-title":"Am J Clin Dermatol"},{"key":"1644_CR51","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jaad.2021.01.012","volume":"84","author":"CE Jo","year":"2021","unstructured":"Jo CE, Finstad A, Georgakopoulos JR, Piguet V, Yeung J, Drucker AM. Facial and neck erythema associated with dupilumab treatment: a systematic review. J Am Acad Dermatol. 2021;84:1339\u201347.","journal-title":"J Am Acad Dermatol"},{"key":"1644_CR52","doi-asserted-by":"publisher","first-page":"ljae266.081","DOI":"10.1093\/bjd\/ljae266.081","volume":"191","author":"AP Quick","year":"2024","unstructured":"Quick AP, Hurton LV, Zolochevska O, Farberg AS, Goldberg MS, Silverberg JI. Contemporary systemic treatment patterns in atopic dermatitis. Br J Dermatol. 2024;191:ljae266.081.","journal-title":"Br J Dermatol"},{"key":"1644_CR53","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/17512433.2020.1767590","volume":"13","author":"YC Tsai","year":"2020","unstructured":"Tsai YC, Tsai TF. Switching biologics in psoriasis\u2014practical guidance and evidence to support. Expert Rev Clin Pharmacol. 2020;13:493\u2013503.","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01644-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01644-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01644-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:03:37Z","timestamp":1772006617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01644-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1644"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01644-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jonathan I. Silverberg has received grants and\/or personal fees from AbbVie, AFYX Therapeutics, Arena Pharmaceuticals, Asana BioSciences, Bluefin Biomedicine, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly and Company, Galderma, GlaxoSmithKline, Incyte Corporation, Kiniksa, LEO Pharma, Luna Pharma, Menlo Therapeutics, Novartis, Pfizer, Rapt Therapeutics, Regeneron, and Sanofi. Lindsay Ackerman has received honoraria as an advisory board member, consultant, and\/or speaker and served as an investigator for AbbVie, Amgen, Apollo Therapeutics, argenx, AstraZeneca, Biofrontera, Bristol Myers Squibb, Castle Biosciences, ChemoCentryx, CorEvitas, Corrona, DermTech, Eli Lilly and Company, Exact Sciences, GlaxoSmithKline, Helsinn Healthcare, IgGenix, Incyte Corporation, Janssen, Kymera Therapeutics, Kyowa Kirin, LEO Pharma, Lilly ICOS, Mindera, Novartis, Regeneron, Replimune, Sanofi, Sun Pharma, Takeda, Timber Pharmaceuticals, Trevi Therapeutics, and UCB Pharma. Jerry Bagel has received research funds payable to the Psoriasis Treatment Center of New Jersey from AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Brickell Biotech, Bristol Myers Squibb, Celgene Corporation, Corrona, Dermavant, Dermira, Eli Lilly and Company, Janssen, Kadmon Corporation, LEO Pharma, Menlo Therapeutics, Mindera, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, TARGET PharmaSolutions, Taro Pharmaceutical Industries, UCB Pharma, and Valeant Pharmaceuticals and has received consultant fees or speaker fees from AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Incyte Corporation, Janssen, Mindera, Novartis, and UCB Pharma. Linda Stein Gold is an investigator, consultant, and\/or speaker for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Galderma, Incyte Corporation, Janssen, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, and UCB Pharma. Andrew Blauvelt has received consulting fees, speaker honoraria, and\/or served as a clinical study investigator for AbbVie, Abcentra, ACELYRIN, Aclaris Therapeutics, Affibody, Aligos Therapeutics, Allakos Therapeutics, Almirall, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis, Arena Pharmaceuticals, ASLAN Pharmaceuticals, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Concert Pharmaceuticals, CTI BioPharma, Dermavant, EcoR1 Capital, Eli Lilly and Company, Escient Pharmaceuticals, Evelo Biosciences, Evommune, Forte Biosciences, Galderma, HighlightII Pharma, Incyte Corporation, Innovent Bio, Janssen, Landos Biopharma, LEO Pharma, Lipidio Pharma, Microbion Biosciences, Merck, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon Therapeutics, Pfizer, Q32 Bio, Rani Therapeutics, RAPT Therapeutics, Regeneron, Sanofi, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, UNION Therapeutics, Ventyx Biosciences, Vibliome Therapeutics, and Xencor. David Rosmarin has received honoraria as a consultant, received research support, conducted trials, and\/or served as a speaker for AbbVie, Abcuro, AltruBio, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert Pharmaceuticals, CSL Behring, Dermavant, Dermira, Eli Lilly and Company, Galderma, Incyte Corporation, Janssen, Kyowa Kirin, Merck, Nektar, Novartis, Pfizer, RAPT Therapeutics, Recludix Pharma, Regeneron, Revolo Biotherapeutics, Sanofi, SUN Pharma, UCB Pharma, Viela Bio, and Zura Bio and is an editorial board member of\n                      Dermatology and Therapy\n                      . David Rosmarin was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Raj Chovatiya has served as an advisory board member, consultant, and\/or investigator for AbbVie, Apogee, Arcutis, Arena Pharmaceuticals, argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, EPI Health, Incyte Corporation, LEO Pharma, L\u2019Or\u00e9al, National Eczema Association, Pfizer, Regeneron, Sanofi, and UCB Pharma; has served as a speaker for AbbVie, Arcutis, Dermavant, Eli Lilly and Company, EPI Health, Incyte Corporation, LEO Pharma, Pfizer, Regeneron, Sanofi, and UCB Pharma; and is an editorial board member of\n                      Dermatology and Therapy\n                      . Raj Chovatiya was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Matthew Zirwas has served as a consultant, investigator, and\/or speaker for AbbVie, Acrotech Biopharma, Advanced Derm Solutions, Aldeyra Therapeutics, all\u00ae free clear, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis, Bausch\u2009+\u2009Lomb, Biocon, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Concert Pharmaceuticals, Dermavant, Edesa Biotech, Evelo Biosciences, Galderma, Genentech, Incyte Corporation, Janssen, L\u2019Or\u00e9al, LEO Pharma, Level Ex, Eli Lilly and Company, LUUM, Meta, Nimbus Therapeutics, Novan, Novartis, Pfizer, Sanofi Regeneron, Trevi Therapeutics, UCB Pharma, Verrica Pharmaceuticals, and WCG Trifecta. Gil Yosipovitch has conducted clinical trials for or received research funds and\/or honoraria for serving on the scientific advisory boards of AbbVie, Arcutis, Eli Lilly and Company, Escient Pharmaceuticals, Galderma, Kiniksa Pharmaceuticals, LEO Pharma, Novartis, Pfizer, Regeneron, and Sanofi. Jill Waibel has served as a consultant and\/or investigator and\/or on scientific advisory boards for Allergan, Amgen, argenx, BellaMia, Bristol Myers Squibb, Candela Healthcare, Cytrellis Biosystems, Eli Lilly and Company, Emblation, Galderma, Horizon, Janssen\/Johnson & Johnson, Lumenis, Neuronetics, Pfizer, Procter & Gamble, RegenX, Sanofi, SkinCeuticals, Shanghi Biopharma, and Port Wine Birthmark and is a recipient of a VA Merit Grant for Amputated Veterans. Jenny E. Murase is on the speaker\u2019s board for non-branded disease state management talks for UCB Pharma; has served on advisory boards for Eli Lilly and Company, LEO Pharma, Sanofi Genzyme, and UCB Pharma; and provided dermatologic consulting services for AbbVie and UpToDat. Ben Lockshin has received grants and\/or research support from AbbVie, Dermira, Franklin Bioscience, Galderma, Incyte Corporation, Pfizer, Regeneron, and Sanofi. Jamie Weisman has been a speaker and\/or investigator for and\/or has received grants and\/or honoraria from AbbVie, Amgen, Biogen, Boehringer Ingelheim, Celgene, Eli Lilly and Company, Janssen, LEO Pharma, Merck, Novartis, Pfizer, Regeneron, Stiefel, and Valeant Pharmaceuticals. Amber Reck Atwater was an employee of Eli Lilly and Company at the time of this study. She is currently affiliated with Distinctive Dermatology, Vienna VA, USA. Jennifer Proper, Maria Silk, Evangeline Pierce, Maria Lucia Buziqui Piruzeli, Sonia Montmayeur, Christopher Schuster, Maria Jose Rueda, and Sreekumar Pillai are employees and shareholders of Eli Lilly and Company. Jinglin Zhong is an employee of IQVIA. Eric Simpson reports personal fees from AbbVie, Advances in Cosmetic Medical Derm Hawaii, Amgen, AOBiome, Arcutis, Arena Pharmaceuticals, ASLAN Pharmaceuticals, Bristol Myers Squibb, CorEvitas, Dermira, Eli Lilly and Company, Evelo Biosciences, Excerpta Medica, FIDE, Forte Bio RX, Galderma, GlaxoSmithKline, Impetus Healthcare, Incyte Corporation, Innovaderm Reche, Janssen, Johnson & Johnson, Kyowa Kirin, LEO Pharma, MauiDerm, Medscape, Merck, MJH Holding, MLG Operating, Pfizer, Physicians World, PRImE, Recludix Pharma, Regeneron, Revolutionizing Atopic Dermatitis, Roivant, Sanofi Genzyme, Trevi Therapeutics, Valeant, Vindico Medical Education, and WebMD; and has received grants or serves as a principal investigator for AbbVie, Acrotech, Amgen, Arcutis, ASLAN Pharmaceuticals, Castle, CorEvitas, Dermira, Dermavant, Eli Lilly and Company, Incyte Corporation, Kymab, Kyowa Kirin, National Jewish Health, LEO Pharma, Pfizer, Regeneron, Sanofi, Target, and VeriSkin. These potential conflicts of interest have been reviewed and managed by Oregon Health & Science University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was undertaken in accordance with the ethical principles of the Declaration of Helsinki and approved by the institutional review board Advarra (6100 Merriweather Drive Suite 600, Columbia, MD 21044, IRB number Pro00066943) before the study was initiated. Written informed consent was obtained from all patients before enrollment in the study. For patients considered minors, written consent of a parent or legal guardian and assent of the minor were obtained. The authors affirm that human research participants provided written informed consent for publication of all images in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}